Balderton

"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."

"I am really excited to announce DELLI’s $7.2M raise to further ignite growth and expand its offer to makers and consumers alike. DELLI’s success over the year, from the 200 makers already signed up to the app to units sold, highlights that there is space in the market for DELLI and a consumer desire for its service."

"The feedback we are getting from private companies and public sector customers alike is that staff are happier, more productive and have greater financial security once they start using our service."